Given that the expression of CDK5 is increased in all lung malignancies, and that higher expression of CDK5 in patients with lung cancer is associated with a poorer prognosis [27,57,58], CDK5 inhibitors could be used for treating both NSCLC and SCLC. This evidence concerns the gene CDK5 and non-small cell lung carcinoma.